Harker-Murray, P. D., Cole, P. D., Hoppe, B. S., Hodgson, D. C., Beishuizen, A., Garnier, N., . . . Daw, S. (2023 Supplement 16). Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744. Journal of Clinical Oncology, 41, 7515-7516.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Harker-Murray, Paul David, et al. "Response-adapted Therapy (tx) with Nivolumab Plus Brentuximab Vedotin (nivo + BV) Without Autologous Hematopoietic Cell Transplantation (auto-HCT) in Children, Adolescents, and Young Adults (CAYA) with Low-risk Relapsed/refractory (R/R) Classic Hodgkin Lymphoma (cHL): CheckMate 744."
Journal of Clinical Oncology 41 (2023 Supplement 16): 7515-7516.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Harker-Murray, Paul David, et al. "Response-adapted Therapy (tx) with Nivolumab Plus Brentuximab Vedotin (nivo + BV) Without Autologous Hematopoietic Cell Transplantation (auto-HCT) in Children, Adolescents, and Young Adults (CAYA) with Low-risk Relapsed/refractory (R/R) Classic Hodgkin Lymphoma (cHL): CheckMate 744."
Journal of Clinical Oncology, vol. 41, 2023 Supplement 16, pp. 7515-7516.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.